Thinly traded nano cap Genetic Technologies Limited (GENE +21.6%) is up on almost a 5x surge in volume, albeit on turnover of only 149K shares, in response to its announcement that sales of its third-generation breast cancer test should commence next quarter.
The company aims to set up 12 clinical sites to demonstrate utility, user experience, reimbursement and distribution.
The test, called Genetype for Breast Cancer, predicts the risk of disease by combining DNA and mammography data.
https://seekingalpha.com/news/3525576-genetic-tech-up-22-on-pending-launch-of-breast-cancer-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.